The number of hypothesis tests is problematic (alpha inflation / familywise error rate) and the authors simply mention, "Another limitation was that we did not correct for multiple tests in the analyses as this was a pilot trial."

However, identifying their study as a pilot study does not excuse the lack of correction for multiple tests. These procedures are well known so failing to use them leads to maximum likelihood of ending up with false positives. The study then provides the best case scenario with the highest likelihood for false positives and seems to highlight the authors' desire to avoid failures to detect effects.

There is always a statistical trade off between reducing the numbers of failures to detect and reducing the number of false positives, so readers will be left to their own devices to decide if the authors' approaches and interpretations were justified.

The study's strength of argument is reduced by:
* The authors' self-description of the study as a pilot study with a small sample size,
* no corrections for multiple testing,
* use of a non-representative sample ("Only approximately 15% of the screened volunteers were included in the study, and our recruitment method yielded a sample of motivated, educated, physically healthy subjects concerned about age-related memory problems. The sample, therefore, was not representative of the general population.")
* PET brain imaging results self-described as "exploratory" (I take the word exploratory to mean "ourselves and others need not trust these results or interpretations" or at least "different results would not be unexpected")

What I find least appealing is the lack of a specific conflict of interest statement even while there is explanation of authors' financial interests in the substance being studied and the company selling it. As noted in the article, "Industry Sponsorship and Financial Conflict of Interest in the Reporting of Clinical Trials in Psychiatry " from the American Journal of Psychiatry ( https://ajp.psychiatryonline.org/doi/abs/10.1176/appi.ajp.16... ), "Author conflict of interest appears to be prevalent among psychiatric clinical trials and to be associated with a greater likelihood of reporting a drug to be superior to placebo." (Perlis et.al, 2005) and this explains the primary conclusions of the current study - better than placebo.

We can't fault the inventors of the substance, holders of the patent, and those with financial interests in the company which sells the product to want to test their product and promote positive findings, but how objective are the investigators and how rigorously are they trying to apply the notion of falsification to their own ideas?

They lose everything with falsification and negative results would undermine the parent company's claims that, "Theracurmin® product is one of the most advanced and studied, highly bioavailable forms of curcumin in the marketplace." http://theravalues.com/english/ . Looking on the research page, there are only a small number of studies shown at http://theravalues.com/english/research-clinical-trials/ . All positive outcomes of course.

All of the current supporting studies are listed at http://theravalues.com/english/literature-published-articles... so does anyone want to open up each of those studies and look at the sample sizes in each one?

In one of the supporting studies for Theracurmin® (https://www.nature.com/articles/srep39551), the sample size was six rats. In a second study (https://www.ncbi.nlm.nih.gov/pubmed/21603867) the sample size was 6 people.

What sample sizes do we see in other studies? How many other studies of this substance are equally as weak in terms of sample size? 6 rats here, 6 people there, 40 people here... not convincing. If anything, the strong marketing hype based on such studies makes me more wary and less trusting of the marketing and scientific claims.

Given the Theravalues clinical trials website promotes the product for for "Progressing malignancies, Mild cognitive impairment (the study highlighted in the parent post), Heart failure / diastolic dysfunction, Cachectic condition, Osteoarthritis, Crohn’s disease, Prostate-Specific Antigen after surgery" I'm left with distrust.

Kudos to the efforts to begin product testing and this sort of research is time consuming and expensive, but studies with sample sizes of 40 people do not support the company's marketing hype. If this study is positive enough for the authors to obtain more grant funding and run a much larger and better clinical study then I would be interested to see what is found then, but happier even still if authors with no financial or personal conflicts of interests ran the study.